1. 1951 Impact of lapatinib (La) treatment duration and endocrine therapy (ET) addition on the efficacy of primary dual HER2 blockage with La and trastuzumab (T) for HER2+ breast cancer (BC) patients. (September 2015) Authors: Bando, H.; Masuda, N.; Nakamura, R.; Kondo, N.; Kuroi, K.; Akiyoshi, S.; Ohtani, S.; Toshimi, T.; Inoue, K.; Yanagida, Y.; Ishiguro, H.; Shimizu, S.; Aogi, K.; Amano, S.; Ozaki, S.; Iguchi-Manaka, A.; Kasai, H.; Morita, S.; Kataoka, T.R.; Toi, M. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S316 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗